We are over dosing anti-CD20 therapy in most people. I know you are fed up with these posts but I need to make comments on this so I can say “I told you so a decade ago”…Someone may pipe up and say they said this way before that…yet we are doing trials on this as we speak. Learn to read and think is a simple answer, but some folks will say we need proof.
When you don’t have a clue how your drug is working you are more likely to do frequent dosing, but undesrtand the biology and you can focus on the important stuff. We are not there yet for many people. However, will the label be changed…unlikely as there is no advantage to the licence holder to do this. There will be people who do not benefit from this.
Elkhooly M, Jacob R, Rempe T. Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis – A meta-analysis. Mult Scler J Exp Transl Clin. 2026 Mar 24;12(1):20552173261432453.
Background: Anti-CD20 therapy is a highly effective multiple sclerosis (MS) disease-modifying therapy, but may be complicated by infections, which has led to the utilization of different extended interval dosing (EID) regimens.
Objectives: To compare the efficacy and safety of standard interval dosing (SID) and EID of anti-CD20 therapy in MS.
Methods: We searched PubMed and MS conference abstracts and included all studies comparing distinct cohorts of people with MS (PwMS) treated with SID and EID of anti-CD20 therapy that reported ≥1 efficacy or safety outcome measure.
Results: Seventeen studies comparing SID to EID were identified, with 1739 (SID) and 1856 (EID) participants. There was no significant difference in frequencies of PwMS with relapses (logOR = 0.15; p = 0.37), MRI activity (logOR = 0.05; p = 0.7), no evidence of disease activity -3 (logOR = 0.33; p = 0.33), serious infections (logOR = 0.46; p = 0.16)……
Conclusions: Data from observational studies suggests that EID of anti-CD20 therapy may have a comparable efficacy and safety profile compared to SID.
CoI Multiple
Disclaimer. My views
Source: multiple-sclerosis-research.org